Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
DRUG REVIEW  

 Article Access Statistics
    Viewed1469    
    Printed36    
    Emailed0    
    PDF Downloaded177    
    Comments [Add]    

Recommend this journal


Click on image for details.

 Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium

Adhi Arya, Sushil Azad, Radhakrishnan Sitaraman
Department of Pediatric Cardiology, Fortis Escorts Heart Institute, New Delhi, India

Correspondence Address:
Dr. Adhi Arya
Fortis Escorts Heart Institute New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/apc.APC_9_20

Rights and Permissions

Year : 2020  |  Volume : 13  |  Issue : 4  |  Page : 334-336

 
SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (575 KB)
Email article
Print Article
Add to My List
Heart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are differences in the etiology, clinical course, and outcome of pediatric heart failure as compared to adult, thus the results of adult heart failure trials cannot be simply extrapolated to pediatric patients. There have been a lot of newer drugs for adults with heart failure, but there is a void for pediatric population with heart failure due to many reasons. Early results of multi-centric randomized control PANORAMA HF Trial and subsequent Food and Drug Administration approval for Angiotensin Receptor and Neprylisin Inhibitor (Sacubitril / Valsartan) for pediatric patients have tried to fill in this void and paved the way for a newer class of drugs for heart failure with proven benefits in pediatric patients.






[FULL TEXT] [PDF]*
 

 

 Whats new | Sitemap | Feedback | Copyright and Disclaimer
 © 2008 Annals of Pediatric Cardiology | Published by Wolters Kluwer - Medknow
 Online since 20th April, 2008

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 DRUG REVIEW
 



Adhi Arya, Sushil Azad, Radhakrishnan Sitaraman
Department of Pediatric Cardiology, Fortis Escorts Heart Institute, New Delhi, India

Correspondence Address:
Dr. Adhi Arya
Fortis Escorts Heart Institute New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/apc.APC_9_20

Rights and Permissions

Heart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are differences in the etiology, clinical course, and outcome of pediatric heart failure as compared to adult, thus the results of adult heart failure trials cannot be simply extrapolated to pediatric patients. There have been a lot of newer drugs for adults with heart failure, but there is a void for pediatric population with heart failure due to many reasons. Early results of multi-centric randomized control PANORAMA HF Trial and subsequent Food and Drug Administration approval for Angiotensin Receptor and Neprylisin Inhibitor (Sacubitril / Valsartan) for pediatric patients have tried to fill in this void and paved the way for a newer class of drugs for heart failure with proven benefits in pediatric patients.






[FULL TEXT] [PDF]*


        
Print this article     Email this article  

 Whats new | Sitemap | Feedback | Copyright and Disclaimer
 © 2008 Annals of Pediatric Cardiology | Published by Wolters Kluwer - Medknow
 Online since 20th April, 2008